Use of ipilimumab resulted in better rates of recurrence-free, overall, and distant metastasis–free survival compared with placebo in people with stage III melanoma in a randomized trial involving 951 individuals. Those who took the drug had more immune-related adverse events.
Patients had previously undergone complete resection, and were randomly assigned to receive ipilimumab 10 mg/kg (n=475) or placebo (n=476) every 3 weeks for 4 doses. They continued therapy every 3 months for up to 3 years. Among the results:
- The 5-year rate of recurrence-free survival was 41% in the ipilimumab group, vs 30% in the placebo cohort.
- Overall survival rates were 65% and 54%, respectively.
- Distant metastasis–free survival rates were 48% and 39%, respectively.
- Grade 3 or 4 adverse event rates were 54% and 26%, respectively.
- Grade 3 or 4 immune-related adverse event rates were 41% and 3%, respectively; 5 patients in the ipilimumab group died due to immune-related adverse events.
Eggermont A, Chiarion-Sileni V, Grob J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. [Published online ahead of print October 8, 2016]. N Engl J Med. doi:10.1056/NEJMoa1611299.
This Week's Must Reads
Program reduces ER admissions and inpatient costs, Mendenhall M et al. Quality Care Symposium, Abstract 30
Pain severity decreased over time with app, Kamdar MM et al. PallOnc 2018, Abstract 76
National health care spending growth slowed to 3.9% in 2017 , Martin A et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05085
Medicare Part D rules on protected medication classes could change, Federal Register (83 FR 62152)
Federal proposal aims to move doctors back to face-to-face interventions, Office of the National Coordinator for Health IT
Must Reads in Melanoma
Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514
Checkpoint inhibitor combo continues to show benefit for advanced melanoma, Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9
Nivolumab safe and effective for cancer patients with HIV, Gobert et al. ESMO 2018, Abstract 1213P_PR.
Nivolumab plus ipilimumab ups survival in melanoma patients with brain mets, Tawbi HA et al. N Engl J Med. 2018 Aug 23. doi: 10.1056/NEJMoa1805453
Pregnancy does not increase melanoma recurrence risk, DiSano JA et al. J Surg Res. 2018 Jun 16. doi: 10.1016/j.jss.2018.05.026.